SyS has unique pathologic and genomic characteristics,including histologic subtypes, biphasic and monophasic, and a characteristictranslocation, t(X; 18) (p11.2; q11.2). This translocation is believed to be an early event, as the fusion type is concordant in primary tumors and metastases and constant throughout the disease.
It occurs in more than 95% of the synovial sarcomas, making it a frequently used diagnostic criterion. Other genomic characteristics such as the B-cell lymphoma 6 corepressor (BCOR) upregulation and the immunoreaction of the nuclear tumor suppressor gene SMRRCB1/INI1 (INI1) were not found to be associated with a worse prognosis. SyS is one of the most common STS subtypes to express NY-ESO-1; greater than 80% of synovial tumors express NY-ESO-1, which is associated with a worse prognosis.
It covers the details of conventional and current medicaltherapies and diagnosis available in the synovial sarcoma market to treat thecondition. It also provides the country-wise treatment guidelines and algorithms across the United States, Europe, and Japan.
The DelveInsight synovial sarcoma market report gives athorough understanding of synovial sarcoma symptoms by including diseasedefinition, symptoms, causes, physiology, and diagnosis. It also provides synovial sarcoma symptoms of treatment algorithms and treatment guidelines for synovial sarcoma symptoms in the US, Europe, and Japan.
